Research publications | Alfred Health

Developing tailored theoretically informed goal-setting interventions for rehabilitation services: a co-design approach

Baker A, Cornwell P, Gustafsson L, Stewart C, Lannin NA

(2022), BMC Health Serv Res, 22(1), 811

An exploration of goal-setting practices in Queensland rehabilitation services

Baker A, Cornwell P, Gustafsson L, Lannin NA

(2022), Disabil Rehabil, 44(16), 4368-78

DOI: 10.1080/09638288.2021.1906957

Implementation of a leisure reintegration programme for people with acquired brain injury in a community rehabilitation programme: a feasibility study

Alves-Stein S, George S, Lannin NA, Jolliffe L

(2022), BRAIN IMPAIR, 1-3

DOI: 10.1017/BrImp.2022.8

Monitoring quality of care in hepatocellular carcinoma: A modified Delphi consensus

Maharaj AD, Lubel J, Lam E, Clark PJ, Duncan O, George J, Jeffrey GP, Lipton L, Liu H, McCaughan G, Neo EL, Philip J, Strasser SI, Stuart K, Thompson A, Tibballs J, Tu T, Wallace MC, Wigg A, Wood M, Zekry A, Greenhill E, Ioannou LJ, Ahlenstiel G, Bowers K, Clarke SJ, Dev A, Fink M, Goodwin M, Karapetis CS, Levy MT, Muller K, O'Beirne J, Pryor D, Seow J, Shackel N, Tallis C, Butler N, Olynyk JK, Reed-Cox K, Zalcberg JR, Roberts SK

(2022), Hepatol Commun, 6(11), 3260-70

DOI: 10.1002/hep4.2089

Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors

Papadatos-Pastos D, Yuan W, Pal A, Crespo M, Ferreira A, Gurel B, Prout T, Ameratunga M, Chénard-Poirier M, Curcean A, Bertan C, Baker C, Miranda S, Masrour N, Chen W, Pereira R, Figueiredo I, Morilla R, Jenkins B, Zachariou A, Riisnaes R, Parmar M, Turner A, Carreira S, Yap C, Brown R, Tunariu N, Banerji U, Lopez J, de Bono J, Minchom A

(2022), J Immunother Cancer, 10(6), e004495

DOI: 10.1136/jitc-2022-004495

A phase 1 safety and bioimaging trial of antibody DS-8895a against EphA2 in patients with advanced or metastatic EphA2 positive cancers

Gan HK, Parakh S, Lee FT, Tebbutt NC, Ameratunga M, Lee ST, O'Keefe GJ, Gong SJ, Vanrenen C, Caine J, Giovannetti M, Murone C, Scott FE, Guo N, Burvenich IJG, Paine C, Macri MJ, Kotsuma M, Senaldi G, Venhaus R, Scott AM

(2022), Invest New Drug, 40(4), 747-55

DOI: 10.1007/s10637-022-01237-3

Dual αV-integrin and neuropilin-1 targeting peptide CEND-1 plus nab-paclitaxel and gemcitabine for the treatment of metastatic pancreatic ductal adenocarcinoma: a first-in-human, open-label, multicentre, phase 1 study

Dean A, Gill S, McGregor M, Broadbridge V, Järveläinen HA, Price T

(2022), LANCET GASTROENTEROL, 7(10), 943-51

DOI: 10.1016/S2468-1253(22)00167-4

Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial

Tesileanu CMS, Sanson M, Wick W, Brandes AA, Clement PM, Erridge SC, Vogelbaum MA, Nowak AK, Baurain JF, Mason WP, Wheeler H, Chinot OL, Gill S, Griffin M, Rogers L, Taal W, Rudà R, Weller M, McBain C, van Linde ME, Aldape K, Jenkins RB, Kros JM, Wesseling P, von Deimling A, Hoogstrate Y, de Heer I, Atmodimedjo PN, Dubbink HJ, Brouwer RWW, van IJcken WFJ, Cheung KJ, Golfinopoulos V, Baumert BG, Gorlia T, French PJ, van den Bent MJ

(2022), Clin Cancer Res, 28(12), 2527-35

DOI: 10.1158/1078-0432.CCR-21-4283

Laryngoscopy diagnosis of inducible laryngeal obstruction during supervised challenge for suspected anaphylaxis

Stojanovic S, Zubrinich C, Sverrild A, Mahoney J, Denton E, Lee J, Hew M

(2022), Clin Exp Allergy, 52(8), 924-8

DOI: 10.1111/cea.14156

POTential in POT: Insights and practical application

Tomolo, Gracie

(2022), Journal of Clinical Practice in Speech Pathology, 24(1), 1-7

DOI: 10.1080/22087168.2022.12370344

Age-Based Trends in Cognitive-Communication Management for Adults in Subacute Rehabilitation Following New Onset Traumatic Brain Injury

Shorland J, Douglas J, O'Halloran R

(2022), AM J SPEECH-LANG PAT, 31(6), 2557-68

DOI: 10.1044/2022_AJSLP-21-00357

Delayed Gastric Emptying After Sleeve Gastrectomy Is Associated with Poor Weight Loss

Wickremasinghe AC, Johari Y, Laurie C, Shaw K, Playfair J, Beech P, Yue H, Becroft L, Hebbard G, Yap KS, Brown W, Burton P

(2022), Obes Surg, 32(12), 3922-31

DOI: 10.1007/s11695-022-06323-2

Noninvasive Assessment of Acute Graft-Versus-Host Disease of the Gastrointestinal Tract After Allogeneic Hemopoietic Stem Cell Transplantation Using 18F-FDG PET

Cherk MH, Khor R, Barber TW, Yap KSK, Patil S, Walker P, Avery S, Roberts S, Kemp W, Pham A, Bailey M, Kalff V

(2022), J Nucl Med, 63(12), 1899-1905

DOI: 10.2967/jnumed.121.263688

Landscape of clinical trials across the pancreatic cancer care continuum: an Australian perspective

Khan NN, Basrai H, Evans SM, Ioannou LJ, Pilgrim CH, Zalcberg JR, Jones GM, Hanson S

(2022), MED J AUSTRALIA, 217(10), 505-9

DOI: 10.5694/mja2.51756

Impact of the evolution in RAS mutation analysis in Australian patients with metastatic colorectal cancer

Chong CY, Jalali A, Wong HL, Loft M, Wong R, Lee M, Gately L, Hong W, Shapiro J, Kosmider S, Tie J, Ananda S, Yeung JM, Ma B, Burge M, Jennens R, Tran B, Lee B, Lim L, Dean A, Nott L, Gibbs P

(2022), ASIA-PAC J CLIN ONCO, 18(5), e363-8

DOI: 10.1111/ajco.13728

Synoptic CT scan reporting of pancreatic adenocarcinoma to align with international consensus guidelines on surgical resectability: a Victorian pilot

Pilgrim CHC, Maciejewska A, Ayres N, Ellis S, Goodwin M, Zalcberg JR, Haydon A

(2022), ANZ J Surg, 92(10), 2565-70

DOI: 10.1111/ans.17999

BMS-986012, an Anti-Fucosyl-GM1 Monoclonal Antibody as Monotherapy or in Combination With Nivolumab in Relapsed/Refractory SCLC: Results From a First-in-Human Phase 1/2 Study

Chu Q, Leighl NB, Surmont V, van Herpen C, Sibille A, Markman B, Clarke S, Juergens RA, Rivera MA, Andelkovic V, Rudin CM, Snow S, Kim DW, Sanatani M, Lin H, Sanghavi K, Tannenbaum-Dvir S, Basciano P, Lathers D, Urbanska K, Kollia G, He C, DiPiero A, Liu Y, Ready N

(2022), Journal of thoracic oncology clinical and research reports, 3(11), 100400

DOI: 10.1016/j.jtocrr.2022.100400

BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extraterminal Domain Proteins, in Patients with Selected Advanced Solid Tumors: Results from a Phase 1/2a Trial

Hilton J, Cristea M, Postel-Vinay S, Baldini C, Voskoboynik M, Edenfield W, Shapiro GI, Cheng ML, Vuky J, Corr B, Das S, Apfel A, Xu K, Kozicki M, Ünsal-Kaçmaz K, Hammell A, Wang G, Ravindran P, Kollia G, Esposito O, Coker S, Diamond JR

(2022), Cancers, 14(17), 4079

DOI: 10.3390/cancers14174079

Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial

Bauer S, Jones RL, Blay JY, Gelderblom H, George S, Schöffski P, von Mehren M, Zalcberg JR, Kang YK, Razak AA, Trent J, Attia S, Le Cesne A, Su Y, Meade J, Wang T, Sherman ML, Ruiz-Soto R, Heinrich MC

(2022), J Clin Oncol, 40(34), 3918-28

DOI: 10.1200/JCO.22.00294

Early Death After Chemotherapy as a Quality Indicator-Is It Time to Bench the Benchmark?

Dunn C, Gately L, Gibbs P

(2022), JAMA Oncol, 8(11), 1559-60

DOI: 10.1001/jamaoncol.2022.1856